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ABSTRACT
Background: This study aimed to investigate the cardiac manifestations of coronavirus 
disease 2019 (COVID-19).
Methods: From February to March 2020, we prospectively and retrospectively 
enrolled consecutive patients diagnosed with COVID-19. Patient's data such as the 
demographic characteristics, symptoms, vital signs, laboratory and radiologic findings, 
electrocardiographic, and echocardiographic data, including the global longitudinal strain 
(GLS) of both ventricles, were obtained.
Results: Forty patients (median age, 58 years; 50% men) were enrolled in the initial analysis. 
Patients were classified into severe and nonsevere groups based on the current guidelines. The 
13 patients in the severe group were significantly older, had a greater prevalence of bilateral 
pneumonia and leukocytosis, and higher aspartate transaminase levels than patients in the 
nonsevere group. Patients in the severe group had a slightly lower left ventricular ejection 
fraction (LVEF) than those in the nonsevere group (median [interquartile range], 61.0% 
[58.5%, 62.3%] vs. 66.7% [60.6%, 69.8%], P = 0.015). In a subgroup of 34 patients in whom 
GLS could be analyzed, patients in the severe group had a significantly impaired left ventricular 
GLS (LVGLS) than those in the nonsevere group (−18.1% [−18.8%, −17.1%] vs. −21.7% [−22.9%, 
−19.9%], P = 0.001). There were no significant differences in total wall (RVGLStotal, −19.3%
[−23.9%, −18.4%] vs. −24.3% [−26.0%, −22.6%], P = 0.060) and free wall (RVGLSfw, −22.7%
[−27.2%, −18.6%] vs. −28.8% [−30.4%, −24.1%], P = 0.066) right ventricle GLS (RVGLS).
Conclusion: Patients with severe COVID-19 had lower LVEF and LVGLS. RVGLS was not 
different between patients with severe and nonsevere COVID-19.
Keywords: Coronavirus; COVID-19; Echocardiography; Global Longitudinal Strain;  
Ejection Fraction; Disease Severity
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INTRODUCTION
In November 2019, an outbreak of unexplained pneumonia occurred in Wuhan, China, and 
the causative pathogen was identified as severe acute respiratory syndrome coronavirus 
2.1 This disease, named coronavirus disease 2019 (COVID-19), was declared a pandemic, 
and as of May 6, 2020, more than 3.5 million cases had occurred in 6 continents and 
247,000 patients died, resulting in a mortality rate of 6.9%.2 An analysis of 1,099 patients 
in China showed that 5.0% of patients needed intensive care and 2.3% needed mechanical 
ventilation.3 Older patients and those with comorbid hypertension, diabetes, coronary 
artery disease, heart failure, chronic obstructive pulmonary disease, cardiac arrhythmia, 
and current smoking had a higher mortality risk.4-6 Approximately 23% of patients with 
COVID-19 who needed critical care had myocardial injuries,7 which were also associated with 
fatal outcomes.6 However, the cardiac manifestations in patients with COVID-19 are not 
well known, and no prospective study has analyzed the cardiac manifestations of COVID-19. 
Thus, this study aimed to investigate the cardiac manifestations of COVID-19 to provide 
information relevant for the management and treatment of this pandemic disease.
METHODS
Study sample
From February to March 2020, we prospectively and retrospectively enrolled consecutive 
patients who were diagnosed with COVID-19 by reverse-transcriptase polymerase-chain-
reaction assay before admission in three referral centers and one COVID-19-dedicated 
hospital. The subjects were classified into nonsevere and severe disease according to the 
current guidelines on community-acquired pneumonia.8 From the 4 medical centers, 28 
and 14 patients were enrolled prospectively and retrospectively, respectively. Among them, a 
5-year-old girl and 1 patient with subcutaneous emphysema whose echocardiographic data 
could not be obtained were excluded. Finally, 40 subjects were enrolled in the initial analysis 
to examine the cardiac manifestations of COVID-19 (Supplementary Fig. 1).
Clinical data collection
The patients' data were retrieved from each institution's electronic medical records. We 
obtained demographic data, symptoms, vital signs, laboratory and radiologic findings, 
and electrocardiographic data. All laboratory tests were performed at the discretion of the 
physicians. The final follow-up date was April 4, 2020.
Electrocardiography (ECG)
All but one patient underwent ECG examination during hospitalization. Heart rate, rhythm, 
PR interval, QRS duration, QT interval, and corrected by Bazett's formula were measured. A 
corrected QT (QTc) > 470 ms, the 99th percentile value in the health population of both sexes 
after prepuberty, was considered a prolonged QTc.9
Conventional transthoracic echocardiography (TTE)
Bedside TTE was performed in all patients using Vscan (1 patient) (GE Healthcare, 
Milwaukee, WI, USA), LOGIQ V2 (27 patients) (GE Healthcare), Lumify (5 patients) (Philips, 
Bothell, WA, USA), and CX50 (7 patients) (Philips). The examiners at each hospital wore 
level-D personal protective equipment during the TTE exam. To prevent the iatrogenic spread 
of infection, the TTE vendor and transducer were sterilized for 3 days after all the patients 
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in each ward were examined. TTE was performed using portable ultrasound machines that 
could not export exam data in a DICOM file format in 2 hospitals.
The median time from admission to the TTE exam was 14 days (5 days in the severe group 
and 15 days in the nonsevere group). Two-dimensional (2D) conventional measurements 
were acquired based on the guidelines of the American Society of Echocardiography.10 
Doppler measurements of pulse wave velocity on the mitral inflow and ejection fraction using 
the biplane Simpson's method were available for 34 of 40 patients. Tissue Doppler velocity, 
estimated right ventricular systolic pressure using the velocity of tricuspid regurgitation, 
and tricuspid annular plane systolic excursion (TAPSE) were measured only in the severe 
COVID-19 group using the CX50 device.
Speckle-tracking echocardiography (STE)
The DICOM files of the echocardiographic images of 34 patients were sent to the core 
laboratory at Yongin Severance Hospital. STE analyses were conducted according to the 
recommendations of the American Society of Echocardiography and European Association 
of Cardiovascular Imaging.11 All strain analysis images were recorded at least 50 frames 
per second to ensure a reliable analysis. The analysis was conducted by an experienced 
sonographer (not involved the present study) who was blinded to the patients' information 
using vendor-independent 2D Cardiac Performance Analysis software (TomTec Imaging 
System, Munich, Germany). In brief, the endocardial ventricle borders were manually traced 
on the end-systolic frames in the apical 4-chamber, 2-chamber, 3-chamber, and right ventricle 
(RV)-focused apical 4-chamber views when the global longitudinal strain (GLS) was measured, 
with end-systole defined as the smallest left ventricle (LV) or RV volume during the cardiac 
cycle. The software tracks speckles along the ventricular endocardial border and myocardium 
throughout the cardiac cycle. The average GLS of the LV (LVGLS) (Fig. 1), RV total wall GLS 
(RVGLStotal) including the interventricular septum, and the RV free wall GLS (RVGLSfw) were 
calculated. Negative strain values indicate contraction and tissue shortening, and thus a higher 
value (i.e., a lower absolute value) represents poorer ventricular systolic function.
Measurement reproducibility
Inter- and intra-observer variabilities for measurements of GLS were assessed in all available 
patients. To determine intra-observer variability, the same analyzer repeated measurement 
for GLS for each selected patient at a separate time point. Additionally, inter-observer 
variability for measurements of GLS was assessed by the second observer who was blinded to 
the first analyzer's measurements.
Statistical analysis
Continuous variables were presented as median [interquartile range] and compared using 
Mann-Whitney U test. Categorical variables were presented as absolute frequencies and 
percentages and compared using Fisher's exact test. Logistic regression and receiver 
operating characteristics (ROC) curve analysis were performed to evaluate the diagnostic 
performance of echocardiographic parameters for classifying severity. Although calculating 
sample size for logistic regression is a complex problem, Peduzzi et al.12 suggested that one 
variable per 10 to 15 patients could be used for adjustment without overfitting. Therefore, 
to alleviate overfitting concerns with our cohort of 34 patients, we used a maximum of two 
variables for adjustment in multivariable logistic regression analysis. All statistical analyses 
were performed using R version 3.6.0 software (R Development Core Team, Vienna, Austria) 
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and SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA). A two-sided P value of < 
0.05 was considered statistically significant.
Ethics statement
All patients enrolled the prospective cohort provided informed consent. This was 
a prospective and retrospective cohort study. The study design was approved by the 
Institutional Review Board (IRB) of each center (IRB No. 9-2020-0014 at Yongin Severance 
Hospital and Chungju Medical Center, 4-2020-0425 at Severance Hospital, and YUMC 2020-
04-026-001 at Yeungnam University Medical Center, 2020-05-090 at Keimyung University 
Dongsan Hospital) and the study was conducted in accordance with the Declaration 
of Helsinki.13 The IRB waived the need for informed consent from patients who were 
retrospectively included owing to the study's retrospective nature and the absence of patients' 
identification in the data presented.
RESULTS
Baseline characteristics and subjective findings and management
The baseline clinical characteristics of the total population are summarized in Table 1. Half 
of the 40 enrolled patients (age, 58.0 [43.0, 69.0] years) were men. Thirteen patients were 
classified into the severe group and required intensive care unit care at enrollment. The median 
body mass index was 22.9 [21.2, 25.2] kg/m2 and there was no significant difference between 
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Average LVGLS = −18.4% Average LVGLS = −21.7%
A B
Fig. 1. Left venticicular global longitudinal strain obtained from 2-dimensional speckle tracking echocardiography according to disease severity in coronavirus 
disease 2019 patients. (A) Representative image of a patient in the severe group; (B) Representative image of a patient in the nonsevere group. 
LVGLS = left venticicular global longitudinal strain.
the groups. Dyspnea, febrile sensation, and history of hypertension (61.5% vs. 25.9%, P = 
0.041). were significantly more frequent in the severe group than in the nonsevere group. One 
patient in the severe group had ageusia. Inotropic agents were more frequently needed in the 
severe group; mechanical ventilators were used in 8 of 13 patients. Veno-venous extracorporeal 
membrane oxygenation supports were provided in 4 patients in the severe group.
Physical, radiological, and laboratory findings
The respiratory rate was significantly higher in the severe group than in the nonsevere group 
(Table 2). There was no significant difference in body temperature between the groups. The 
severe group had more serious form of pneumonia on plain chest radiographs: increased 
bilateral infiltration and greater frequency of lobar pneumonia than bronchopneumonia. 
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Table 1. Baseline characteristics of the patients according to disease severity
Characteristics Severe group (n = 13) Nonsevere group (n = 27) P value
Age, yr 69.0 (62.0–72.0) 54.0 (41.5–62.5) 0.012
Male, sex 7 (53.8) 13 (48.1) > 0.999
Body mass index, kg/m2 22.8 (21.3–25.4) 23.1 (21.3–24.9) 0.840
Underlying disease
Hypertension 8 (61.5) 7 (25.9) 0.041
Diabetes mellitus 4 (30.8) 3 (11.1) 0.187
Coronary artery disease 0 (0.0) 0 (0.0) > 0.999
Heart failure 0 (0.0) 0 (0.0) > 0.999
COPD/asthma 0 (0.0) 1 (3.7) > 0.999
Chronic kidney disease 0 (0.0) 1 (3.7) > 0.999
Current medication
RAS blockers 6 (46.2) 5 (18.5) 0.146
Beta-blockers 2 (15.4) 0 (0.0) 0.100
Calcium channel blockers 3 (23.1) 3 (11.1) 0.370
Diuretics 1 (7.7) 1 (3.7) > 0.999
Statins 1 (7.7) 2 (7.4) > 0.999
Oral hypoglycemic agents 2 (15.4) 3 (11.1) > 0.999
Symptoms
No symptoms 0 (0.0) 7 (25.9) 0.077
Cough 3 (23.1) 11 (40.7) 0.316
Sputum 2 (15.4) 4 (14.8) > 0.999
Dyspnea 8 (61.5) 3 (11.1) 0.002
Sore throat 2 (15.4) 4 (14.8) > 0.999
Myalgia 2 (15.4) 5 (18.5) > 0.999
Febrile sensation 12 (92.3) 5 (18.5) < 0.001
Rhinorrhea 1 (7.7) 1 (3.7) > 0.999
Anosmia 0 (0.0) 0 (0.0) > 0.999
Ageusia 1 (7.7) 0 (0.0) 0.325
Chest pain 1 (7.7) 1 (3.7) > 0.999
Nausea/vomiting 2 (15.4) 0 (0.0) 0.100
Diarrhea 1 (7.7) 0 (0.0) 0.325
Vital signs
Systolic blood pressure, mmHg 130.0 (112.0–142.0) 127.0 (122.5–134.0) 0.750
Diastolic blood pressure, mmHg 80.0 (69.0–89.0) 79.0 (73.0–84.0) 1.000
Heart rate, bpm 79.0 (71.0–86.0) 79.0 (68.5–85.5) 0.644
Respiratory rate, cycles per min 22.0 (20.0–28.0) 18.0 (18.0–19.0) < 0.001
Body temperature, °C 37.8 (36.9–38.0) 37.2 (36.5–37.8) 0.686
Therapeutic management
Inotropics 6 (46.2) 0 (0.0) 0.001
Mechanical ventilator 8 (61.5) 0 (0.0) < 0.001
VV-ECMO 4 (30.8) 0 (0.0) 0.013
Renal replacement therapy 1 (7.7) 0 (0.0) 0.705
Values are presented as median (interquartile range) or number (%).
COPD = chronic obstructive pulmonary disease, RAS = renin-angiotensin system, VV-ECMO = veno-venous 
extracorporeal membrane oxygenation.
Eight of 13 patients in the severe group had cardiomegaly compared to none in the nonsevere 
group. Leukocytosis, decreased platelet count, and relative lymphopenia were more 
frequently observed in the severe group. Blood urea nitrogen and aspartate transaminase 
were elevated in the severe group, but glomerular filtration rate was similar between the 
groups (Table 2).
Cardiac-specific biomarkers were identified in the severe group (Supplementary Table 1). 
Of the 12 patients, seven had a higher level of N-terminal pro-brain natriuretic peptide 
(NT-proBNP) (661.8 [154.5, 1,123.8] pg/mL), and five had elevated cardiac troponin-T or 
troponin-I levels. One patient (number 37) had markedly elevated levels of both NT-proBNP 
(1,929 pg/mL) and troponin-I (1.260 ng/mL).
Electrocardiographic findings
All patients enrolled in the study had sinus rhythm. Only one patient developed paroxysmal atrial 
fibrillation during hospitalization. The median heart rate was 72 bpm; 2 patients had inferior Q 
waves but no regional wall motion abnormalities on TTE. Conduction disturbance was detected 
in 3 patients: 2 had right bundle branch block while the other had a left anterior fascicular block. 
There were no differences in ECG parameters, including PR interval, QRS duration, QT interval, 
and QTc, between groups (Supplementary Table 2). Three patients in the severe group had a QTc 
longer than 470 ms compared to none in the nonsevere group (P = 0.029).
Conventional echocardiographic parameters
There were no significant differences in LV end-systolic and end-diastolic volume between 
groups (Table 3). The median left ventricular ejection fraction (LVEF) was 62.6%; LVEF was 
significantly lower in the severe group than in the nonsevere group (61.0% [58.5%, 62.3%] vs. 
66.7% [60.6%, 69.8%], P = 0.015). In the severe group, one patient diagnosed with myocarditis 
had severely depressed LV systolic function (LVEF of 25%). The inferior vena cava diameter at 
expiration was larger in the severe group than in the nonsevere group (18.1 [15.3, 21.7] vs. 13.5 
[11.3, 14.9], P = 0.001) but 8 patients in the severe group were receiving mechanical ventilator 
support. The E/A ratio was significantly lower in the severe group (0.7 [0.7, 0.8] vs. 1.0 [0.8, 
1.5], P = 0.016) but deceleration time showed no difference between groups.
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Table 2. Radiographic and laboratory findings, according to disease severity
Findings Severe group (n = 13) Nonsevere group (n = 27) P value
Chest radiographic findings
Unilateral pneumonia 1 (7.7) 0 (0.0) 0.705
Bilateral pneumonia 8 (61.5) 1 (3.7) < 0.001
Pleural effusion 2 (15.4) 0 (0.0) 0.188
Cardiomegaly 8 (61.5) 0 (0.0) < 0.001
Laboratory findings
White blood cell count, per μL 6.80 (5.10–12.67) 4.58 (4.22–5.25) 0.004
Neutrophils, % 83.4 (78.9–91.0) 62.5 (59.8–68.7) < 0.001
Lymphocytes, % 11.0 (6.0–19.4) 27.3 (20.1–29.7) < 0.001
Hemoglobin, g/dL 11.5 (10.6–14.7) 13.0 (12.2–13.9) 0.339
Platelet count, per μL 159.0 (116.0–210.0) 225.0 (181.0–267.0) 0.041
Blood urea nitrogen, mg/dL 15.0 (13.0–26.0) 11.9 (10.1–14.4) 0.009
Creatinine, mg/dL 0.8 (0.7–1.3) 0.9 (0.8–1.0) 0.666
Estimated GFR, mL/min/1.73 m2 91.8 (49.2–101.7) 84.3 (73.3–93.4) 0.820
AST, IU/L 50.0 (36.0–68.0) 22.0 (18.0–26.5) 0.007
ALT, IU/L 14.0 (13.0–21.0) 24.0 (20.5–30.0) 0.032
Values are presented as median (interquartile range) or number (%).
GFR = glomerular filtration rate, AST = aspartate aminotransferase, ALT = alanine aminotransferase.
Conventional RV parameters, such as RV end-systolic area and fractional area change, were 
also similar between the groups (Table 3).
There were no significant valvular lesions except for aortic valve sclerosis (2 and 1 patients in 
the severe and nonsevere groups, respectively) and mitral annular calcification (1 patient in 
the severe group). One patient in the severe group had scanty amount of pericardial effusion. 
Prominent epicardial fat was seen in a patient in the nonsevere group.
STE analysis
Thirty-four patients whose DICOM video files were available were eligible for STE analysis. 
In this subset, patients in the severe group were significantly older and had more frequent 
history of hypertension than those in the nonsevere group, a similar trend with the total 
population. (Supplementary Table 3).
The interventricular septum was slightly thicker in the severe group. LVEF measured using 
biplane Simpson' method was significantly lower in the severe group (58.4% [52.9%, 59.9%] 
vs. 64.4% [60.9%, 67.9%], P = 0.007) (Fig. 2A), although LVEF was within normal range, that 
is similar trend in total population (Supplementary Table 4).
The severe group had significantly impaired LVGLS value compared to the nonsevere group 
(−18.1% [−18.8%, −17.1%] vs. −21.7% [−22.9%, −19.9%], P = 0.001) (Fig. 2B). There were no 
significant differences in the total and free wall RVGLS between the two groups (RVGLStotal: 
−19.3% [−23.9%, −18.4%] vs. −24.3% [−26.0%, −22.6%], P = 0.060; RVGLSfw: −22.7% 
[−27.2%, −18.6%] vs. −28.8% [−30.4%, −24.1%], P = 0.066] (Fig. 3A and B).
Diagnostic performance of echocardiographic parameters
LVEF (adjusted odds ratio [OR], 0.68; 95% confidence interval [CI], 0.48, 0.96; P = 0.028) 
and LVGLS (OR, 3.05; 95% CI, 1.12, 8.34; P = 0.030) showed good diagnostic performance 
in the logistic regression analysis (Table 4). In the ROC analysis, the area under the curve of 
LVGLS and LVEF were 0.88 (95% CI, 0.77, 0.99) and 0.84 (95% CI, 0.70, 0.98), respectively, 
which was higher than those of RVGLStotal (0.74) and RVGLSfw (0.73) (Supplementary Fig. 2).
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Table 3. Echocardiographic parameters according to disease
Parameters Severe group (n = 13) Nonsevere group (n = 27) P value
LV end-diastolic dimension, mm 45.0 (41.2–48.5) 44.0 (40.5–46.0) 0.360
LV end-systolic dimension, mm 28.2 (23.2–33.0) 28.0 (26.5–31.0) 0.891
LV ejection fraction 61.0 (58.5–62.3) 66.7 (60.6–69.8) 0.015
End-diastolic IVS, mm 9.0 (7.3–9.6) 7.8 (7.0–8.2) 0.033
End-diastolic LV PW, mm 7.2 (6.5–9.1) 8.0 (7.0–8.0) 0.914
LA anterior-posterior diameter, mm 33.0 (27.0–37.4) 32.5 (28.0–35.1) 0.919
LA volume index, mL/m2a 24.2 (20.5–27.2) 28.7 (24.3–34.0) > 0.999
IVC diameter, mm 18.1 (15.3–21.7) 13.5 (11.3–14.9) 0.007
Mitral inflow–E wave, cm/sa 70.1 (63.6–84.3) 69.0 (58.0–77.0) 0.569
Mitral inflow–A wave, cm/sa 99.9 (85.5–116.2) 62.2 (52.3–78.4) 0.001
E/A ratioa 0.7 (0.7–0.8) 1.0 (0.8–1.5) 0.016
Deceleration time of E wave, msa 204.0 (180.0–227.0) 188.0 (161.0–216.0) 0.315
RV end-systolic area, cm2a 9.6 (7.7–10.4) 8.2 (6.3– 9.4) 0.294
RV Fractional area change, %a 48.4 (40.8–49.8) 47.4 (43.9–52.0) 0.588
Values are presented as median (interquartile range).
LV = left ventricle, IVS = interventricular septum, PW = posterior wall, LA = left atrium, IVC = inferior vena cava.
aParameters could be measured 34 of 40 patients with coronavirus disease.
Measurement reproducibility
In analysis of intra-observer variability, there was excellent correlation between two 
measurements. Intraclass correlation coefficients (ICC) for LVGLS, RVGLStotal, and RVGLSfw 
were 0.942, 0.955, and 0.938, respectively (all P < 0.001). Excellent inter-observer variability 
was also found (ICCs for LVGLS, RVGLStotal, and RVGLSfw were 0.963, 0.940, and 0.955; all P 
< 0.001). Bland-Altman plots presented that most of inter-observer differences were within 1 
standard deviation (Supplementary Figs. 3 and 4).
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Fig. 2. Echocardiographic parameters of left ventricle according to disease severity in patients with coronavirus disease 2019. (A) LVEF and (B) LVGLS according 
to disease severity. 



































−24.3 [−26.0, −22.6]−19.3 [−23.9, −18.4]
Fig. 3. Echocardiographic parameters of right ventricle according to disease severity in patients with coronavirus disease 2019. (A) RVGLStotal and (B) RVGLSfw 
according to disease severity. 
RVGLStotal = right ventricle global longitudinal strain of including both the free wall and interventricular septum, RVGLSfw = right ventricular free wall global 
longitudinal strain.
DISCUSSION
The present study is the multicenter prospective and retrospective cohort to evaluate the 
cardiac manifestations in patients with COVID-19. The nonsevere group had a relatively 
hyperdynamic LV systolic function, whereas the severe group, despite administering 
inotropics, had grossly normal but statistically lower LV systolic function and more impaired 
LVGLS. Conventional RV function parameters were similar between the groups but RVGLSfw 
was numerically lower in the severe group.
Except for a patient with myocarditis, normal LVEF was seen on TTE. The normal immune 
responses to infection is to increase the sympathetic tone, which in turn increases heart 
rate and contractility.14-16 In patients with advanced liver disease, although most show 
hyperdynamic LV contractility and high cardiac output, patients with normal or below-
normal LVEF might have a subclinical form of cardiomyopathy or concurrent ischemic heart 
disease.17,18 The severe COVID-19 group also might have a subclinical cardiac condition and 
may reveal normal but slightly lower EF compared with the nonsevere group when in an 
increased inflammatory state and higher adrenergic stimulation, as in the case of infection.
Compared with LVEF, LVGLS may be able to detect subclinical conditions earlier and predict 
the prognosis independently of LVEF in different clinical settings.19-21 The LVGLS in in the 
severe group was slightly lower than that in the nonsevere group and the reference values for 
the general population, although LVEF was within normal range in both the groups.22 The 
mechanisms behind the LVGLS impairment in the severe group were not directly evaluated. 
However, the E/A ratio was significantly lower and deceleration time was numerically delayed 
in the severe group. Additionally, history of hypertension was more frequent in the severe 
group; thus, the diastolic function might be impaired in these patients, which might explain 
the decreased LVGLS in the severe group. Nevertheless, we showed that LVGLS still had a 
good diagnostic ability after adjusting for hypertension in the logistic regression analysis. 
Therefore, LVGLS may be a useful parameter for understanding and managing the cardiac 
manifestations of COVID-19, although it was difficult to demonstrate the casual relationship 
between disease severity and decreased LVGLS. Age showed a significant difference between 
groups at baseline; hence, it was not used for the adjustment in the logistic regression 
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Table 4. Logistic regression analysis of echocardiographic parameters of disease severity diagnostic performance
Parameters OR 95% CI P value
LVEF, per 1% increase
Unadjusted 0.80 0.67–0.96 0.017
Adjusteda 0.68 0.48–0.96 0.028
LVGLS, per 1% increase
Unadjusted 1.99 1.15–3.45 0.014
Adjusteda 3.05 1.12–8.34 0.030
RVGLStotal, per 1% increase
Unadjusted 1.37 1.00–1.87 0.051
Adjustedb 1.43 0.94–2.16 0.095
Adjustedc 1.40 0.97–2.02 0.070
RVGLSfw, per 1% increase
Unadjusted 1.21 1.01–1.47 0.043
Adjustedb 1.52 1.01–2.27 0.044
Adjustedc 1.24 0.96–1.60 0.104
OR = odds ratio, CI = confidence interval, LVEF = left ventricular ejection fraction, LVGLS = left ventricle global 
longitudinal strain, RVGLStotal = right ventricle global longitudinal strain including both the free wall and 
interventricular septum, RVGLSfw = right ventricle free wall global longitudinal strain.
aAdjusted for hypertension; bAdjusted for aspartate transaminase levels and platelet count; cAdjusted for LVGLS.
analysis. Even so, our findings may lead to the evaluation of LVGLS being added to the 
conventional parameters of cardiac function. This may provide additional information for 
physicians to identify patients with COVID-19 who require more careful examination or 
early intensive care, such as those with asymptomatic severe mitral regurgitation or aortic 
stenosis.19-21 Further well-designed studies are needed to prove the causality between LVGLS 
impairment and disease severity in patients with COVID-19.
Based on the structural characteristics of the RV, which has predominantly longitudinally 
oriented muscle fibers, TAPSE has been used as an easily assessable index of RV systolic 
function.23 However, this parameter has inevitable limitations related to its angle 
dependency.24 RVGLS has advantages over other traditional echocardiographic parameters 
examining the RV function,25 and may be superior to TAPSE in predicting cardiovascular 
outcomes.26 A recently published article about RVGLSfw in the patients with COVID-19 
demonstrated that RVGLSfw had significant predictive ability of poor clinical outcomes and 
higher mortality than conventional RV parameters.27 In our study, total and free wall RVGLS 
did not show significant differences between groups but were impaired in the severe group. 
The cutoff value of −23% in RVGLSfw for higher mortality from a previous study also matched 
the median value of the severe group in our study.27 The severe COVID-19 group had more 
extensive lung infiltration, which increases the RV afterload and may lead to subclinical RV 
dysfunction. Although our data revealed a trend that did not reach statistical significance, the 
measurement of RVGLS in patients with COVID-19 in clinical settings may help with the early 
detection of patients who require more intensive care. However, RVGLS might also influence 
LV function, and no significant differences between groups were found after adjusting 
for LVGLS in the logistic regression analysis. Thus, a more comprehensive approach and 
evaluation are required to determine the role of RVGLS in patients with COVID-19.
The present study had some limitations. First, when we first designed this study, the 
incidence of COVID-19 in South Korea was very high. However, during the prospective patient 
enrolment period after obtaining approval from the IRB, the incidence dropped abruptly. 
As a result, we had a relatively small sample size and there was no other option but to have a 
composite of prospective and retrospective designs. In addition, due to the complex vendor 
and transducer sterilization procedures, we could not perform TTE exam on a large number 
patients and, in 2 hospitals, TTE was performed using small size of portable machines that 
could not export examination data in the DICOM file format. Nevertheless, we analyzed 
echocardiographic data from the total sample and in the subset of patients with available STE 
data, and achieved consistent 2D LVEF findings. Second, the time from admission to TTE was 
slightly delayed in the nonsevere group. This was due to the prospective study design, as the 
TTE exam was only performed after IRB approval. Third, the decision to perform laboratory 
tests was left to the discretion of each physician in the prospective part of the study; thus, 
some data, such as cardiac markers, C-reactive protein, D-dimer, and lactate dehydrogenase, 
were not acquired. Finally, since the number of patients in the severe group was small, we 
performed statistical analyses using nonparametric methods and could not apply complex 
methods to investigate further differences regarding the cardiac manifestations of COVID-19 
according to its severity. Well-designed prospective studies are needed to determine the 
impact of STE analysis on both LV and RV function for predicting cardiovascular outcomes.
In conclusion, patients with severe COVID-19 had lower LVEF and impaired LVGLS than those 
with nonsevere COVID-19. RVGLS was not different between the patients with severe and 
nonsevere COVID-19.
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